Drugs / DelNS1-2019-nCoV-RBD-OPT1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05200741 | Feb 2022 → Feb 2024 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05855408 | May 2023 → May 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DelNS1-2019-nCoV-RBD-OPT1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05855408 ↗ |
| Modality | Vaccine | “Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray” NCT05200741 ↗ |
| Route | Intranasal | “intranasal administration” NCT05200741 ↗ |